- Home
- INVE vs GNLX Comparison
INVE vs GNLX Comparison
Compare INVE & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- GNLX
- Stock Information
- Founded
- INVE 1990
- GNLX 2001
- Country
- INVE United States
- GNLX United States
- Employees
- INVE N/A
- GNLX N/A
- Industry
- INVE Computer peripheral equipment
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- GNLX Health Care
- Exchange
- INVE Nasdaq
- GNLX Nasdaq
- Market Cap
- INVE 85.9M
- GNLX 128.0M
- IPO Year
- INVE 1997
- GNLX 2023
- Fundamental
- Price
- INVE $3.95
- GNLX $6.75
- Analyst Decision
- INVE Strong Buy
- GNLX Strong Buy
- Analyst Count
- INVE 2
- GNLX 5
- Target Price
- INVE $5.50
- GNLX $17.40
- AVG Volume (30 Days)
- INVE 32.4K
- GNLX 160.3K
- Earning Date
- INVE 11-06-2025
- GNLX 11-13-2025
- Dividend Yield
- INVE N/A
- GNLX N/A
- EPS Growth
- INVE N/A
- GNLX N/A
- EPS
- INVE 3.12
- GNLX N/A
- Revenue
- INVE $23,538,000.00
- GNLX N/A
- Revenue This Year
- INVE N/A
- GNLX N/A
- Revenue Next Year
- INVE $9.06
- GNLX N/A
- P/E Ratio
- INVE $1.29
- GNLX N/A
- Revenue Growth
- INVE N/A
- GNLX N/A
- 52 Week Low
- INVE $2.86
- GNLX $1.99
- 52 Week High
- INVE $4.29
- GNLX $6.85
- Technical
- Relative Strength Index (RSI)
- INVE 62.39
- GNLX 80.05
- Support Level
- INVE $3.43
- GNLX $4.17
- Resistance Level
- INVE $3.81
- GNLX $5.72
- Average True Range (ATR)
- INVE 0.17
- GNLX 0.47
- MACD
- INVE 0.03
- GNLX 0.15
- Stochastic Oscillator
- INVE 84.80
- GNLX 92.91
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.